Prostate Cancer: Where Are We in 2018?
Estimated time to complete session: 60 mins.
Upon completion of this session, you should be able to:
1. Implement patient education tools on PSA screening benefits and harms to enable patients to make informed choices.
2. Using shared decision-making, assist patients in the informed decision for or against PSA screening.
3. Explain treatment options for patients diagnosed with low-risk prostate cancer, including benefits and harms associated with conservative and invasive management strategies.
View technical requirements (opens in a new window).
View CME credit information (opens in a new window).
View disclosures and disclaimers (opens in a new window).
All materials herein are protected by copyright and are for the sole, personal use of the purchaser. No part of the written, oral, and broadcast production may be copied, duplicated, replicated or retransmitted without the prior permission of the applicable copyright owner.
The unauthorized reproduction or distribution of a copyrighted work is illegal. Criminal copyright infringement, including infringement without monetary gain, is investigated by the FBI and is punishable by up to five years in federal prison and a fine of $250,000.
Joel J. Heidelbaugh, MD, FAAFP, FACG, Clinical Professor, Departments of Family Medicine and Urology, University of Michigan Medical School, Ann Arbor, Michigan
- 1.00 AAFP prescribed